Consumption-based companies have witnessed a sharp fall in their share prices in the last one week. What should you do with funds dedicated to consumption?

Let us have a look at the Version 2.0 of debt mutual funds, post the SEBI’s mutual funds re-categorization which will help you understand the guidelines put forward by SEBI for the fund houses.

SEBI’s new norms on re-categorization of mutual funds have provided guidelines to fund houses to classify their debt mutual funds into categories based on their Macaulay Duration. So, what is this Macaulay Duration and how important is it?

Another PSU, Ircon International, is set for the IPO which will open for subscription from September 17 to September 19, 2018. The issue consists purely of Offer for Sale (OFS) with 99,05,157 equity shares worth Rs 470.49 crore. The face value of the share is Rs 10 per share. The minimum lot size consists of 30 shares. The issue price per equity share is in range of Rs 470-475. Post allotment, the company will get listed on both BSE and NSE.

Tata Power Solar, the wholly-owned subsidiary of Tata Power and the largest solar company in India, has launched an extensive rooftop solution in Mumbai. With this solution, customers would be able to save up to Rs 50,000 annually for the next 25 years.

As per the agreement signed between CLP India and Suzlon Group, CLP India has agreed to acquire 49 per cent stake in Gale Solarfarms Limited and Tornado Solarfarms Limited, two special purpose vehicles (SPV) set‐up by Suzlon.

Yes Bank has successfully closed a USD 400 million syndicated loan facility, borrowed out of the Bank’s IFSC Banking Unit (IBU) in Gujarat International Finance Tec City (GIFT) and will be utilised to support the IBU’s growing business.

Following stocks are close to their 52-week low as at 1.18 p.m. on September 11, 2018.

The markets on September 11, 2018 opened up. BSE Sensex is trading at 37,869.63, down by 52.54 points and the Nifty is trading at 11,423.10, down by 15.00 points.

Global pharmaceutical company, Zydus Cadila has received the tentative approval from USFDA for Sitagliptin.